Herpes Simplex News and Research

RSS

Herpes simplex is a viral disease caused by herpes simplex viruses; both herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) cause herpes simplex. Infection with the herpes virus is categorized into one of several distinct disorders based on the site of infection.

Rutgers Cancer Institute scientist leads phase III trial of FDA-approved viral melanoma therapy

The U.S. Food and Drug Administration has approved a viral melanoma therapy that was the focus of a phase III clinical trial led by Rutgers Cancer Institute of New Jersey Associate Director for Clinical Science and Chief Surgical Officer Howard L. Kaufman, MD, FACS.

29 Oct 2015

Over 3.7 billion people under 50 have genital HSV-1 infection, shows WHO report

More than 3.7 billion people under the age of 50 – or 67% of the population – are infected with herpes simplex virus type 1 (HSV-1), according to the World Health Organization’s first global estimates of HSV-1 infection published today in the journal PLOS ONE.

29 Oct 2015

Amgen's IMLYGIC receives positive opinion from CHMP for treatment of melanoma

Amgen today announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion recommending that IMLYGIC (talimogene laherparepvec) be granted approval for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.

23 Oct 2015

FDA permits marketing of first CSF nucleic acid-based test for detection of multiple pathogens

The U.S. Food and Drug Administration today allowed marketing of the first cerebrospinal fluid (CSF) nucleic acid-based test for simultaneous detection of multiple pathogens that can cause central nervous system infections.

12 Oct 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology 2015 Annual Meeting to be held November 7-11 in San Francisco.

8 Oct 2015

Luminex receives rapid clearance from FDA for ARIES System and ARIES HSV 1&2 Assay

Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay.

7 Oct 2015

Quest Diagnostics receives FDA 510(k) clearance for Simplexa HSV 1 & 2 Direct molecular test

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that its Focus Diagnostics products business has received FDA 510(k) clearance to add the genital swab claim to its Simplexa HSV 1 & 2 Direct molecular test on the Integrated Cycler.

From Quest Diagnostics 4 Sep 2015

Blavatnik Biomedical Accelerator funds advanced biomedical research projects

A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.

20 Aug 2015

Researchers capture images of immune cell interactions rallying to destroy herpes simplex virus

Doctor Scott Mueller and colleagues from the University of Melbourne's Department of Microbiology and Immunology at the Doherty Institute used state-of-the-art microscopy to painstakingly capture images of the interactions of three crucial types of immune cells rallying to destroy herpes simplex virus.

19 Aug 2015

Reducing amyloid fibril levels in semen may help reduce transmission of HIV

There may be two new ways to fight AIDS -- using a heat shock protein or a small molecule - to attack fibrils in semen associated with the human immunodeficiency virus (HIV) during the initial phases of infection, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

18 Aug 2015

NanoViricides speeds up HerpeCide drug development program

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports that it is accelerating its HerpeCide drug development program.

17 Aug 2015

Findings may lead to more accurate diagnostic test, possible vaccine for oral and genital herpes

Findings from a pair of new studies could speed up the development of a universally accurate diagnostic test for human herpes simplex viruses, according to researchers at Johns Hopkins and Harvard universities and the National Institutes of Health.

12 Aug 2015

Anna Nele Meckler and Armelle Corpet to receive SNSF's 2015 Marie Heim-Vögtlin Prize

The biologist Armelle Corpet and paleo-climatologist Anna Nele Meckler will receive the 2015 Marie Heim-Vögtlin (MHV) Prize. This distinction rewards their remarkable scientific work supported by a MHV grant. The prize will be bestowed on 23 September 2015 at the Swiss National Science Foundation.

4 Jun 2015

Roche announces FDA 510(k) clearance for cobas HSV 1 and 2 Test

Roche announced today that the US Food and Drug Administration has provided 510(k) clearance for the cobas HSV 1 and 2 Test for the direct detection and differentiation of HSV-1 and HSV-2 DNA in anogenital specimens from symptomatic patients. With dual target detection and automation, the cobas HSV 1 and 2 Test provides laboratories with the capability to report up to 94 results in significantly less time than traditional methods and provides a simplified workflow for sample handling in the laboratory.

4 Jun 2015

Talimogene laherparepvec treatment shows durable clinical responses in advanced-stage melanoma patients

Research led by Howard L. Kaufman, MD, FACS, associate director for clinical science and chief surgical officer at Rutgers Cancer Institute of New Jersey and colleagues, shows advanced-stage melanoma patients have significant improvement in durable response rate and a trend toward improved survival when treated with a genetically-modified form of a herpes virus, whose native form causes the common cold sore.

2 Jun 2015

Modified cold sore (herpes) virus improves survival in stage IIIb to IV melanoma patients

It's a new weapon in the arsenal of cancer fighting treatments: utilizing genetically modified viruses to invade cancer cells and destroy them from the inside.

1 Jun 2015

Modified herpes virus improves survival in melanoma patients

University of Louisville researcher Jason Chesney, M.D., Ph.D., deputy director of the James Graham Brown Cancer Center, and a team of international scientists found that stage IIIb to IV melanoma patients treated with a modified cold sore (herpes) virus had improved survival.

30 May 2015